
Clinical
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News

























Tumor response rate and progression-free survival were the benchmarks that helped pembrolizumab (Keytruda) gain accelerated approval as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), in combination with chemotherapy.
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL
4
In CLL, New Therapies Offer Potential for Personalized Approaches
5
















































